Kindolor (Lohocla 201) / Lohocla Research - LARVOL DELTA

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Lohocla Research Corporation | N=32 ➔ 16 | Trial completion date: Jul 2025 ➔ Feb 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jul 2025 ➔ Nov 2024; Terminated by sponsor due to low drug bioavailability; no safety concerns were noted.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Pain

A Study to Test the Effects of Kindolor At Different Doses in Healthy Adults (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Lohocla Research Corporation | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2024 ➔ Jul 2025 | Trial primary completion date: Nov 2024 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Pain

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Lohocla Research Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Pain

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Lohocla Research Corporation

New P1 trial • Pain

[VIRTUAL] Lohocla Research Corporation (BIO 2021) - "The NIDA award is for $15.3 million over five years, to bring the companys chronic pain- and opiate-sparing medication, “Kindolor,” through Phase 1 trials...The second stage provides $9.7 million for the completion of Phase 1a and 1b clinical studies. Lohocla Research Corporation is presenting as part of the NIH Innovation Zone."

Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry

Controlling the "Opioid Epidemic": A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain. (PubMed, J Psychiatr Brain Sci) - "The overall goal of the project is to complete the investigational new drug (IND)-enabling preclinical studies of Kindolor, and once IND approval is gained, we will proceed to the clinical Phase Ia and 1b safety studies and a Phase 2a efficacy study. The work is in its second year, and the present report describes progress toward our overall goal of bringing our compound to a full Phase 2 ready stage."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry